Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas
Keywords:
Head and neck neoplasms, Esophageal neoplasms, Antineoplastic combined chemotherapy protocols, Quality of life, Karnofsky performance statusAbstract
CONTEXT AND OBJECTIVE: Patients with advanced head and neck (H/N) and esophageal squamous cell carcinoma (SCC) often have a poor performance status and a dire prognosis. Our aim was to evaluate the feasibility, activity and quality of life (QOL) of an outpatient chemotherapy regimen consisting of cisplatin, 5-fluorouracil and leucovorin (CFL). DESIGN AND SETTING: Prospective phase II study conducted at a Brazilian public institution. METHODS: Fifteen patients with residual, recurrent or metastatic SCC of the H/N or esophagus received bolus infusions of leucovorin 20 mg/m2/day and 5-fluorouracil 370 mg/m2/day on days 1-4, and 90 minutes of infusion of cisplatin 25 mg/m2 /day on days 1-3, every 21 to 28 days, depending on hematological recovery. We also evaluated QOL by applying the European Organization for Research and Treatment of Cancer Quality of Life-C30 questionnaire (EORTC QLQ-C30) before each cycle. RESULTS: The overall response rate was 36%, and the mean overall survival and progression-free survival were six and three months, respectively. We observed grade 3 or higher hematological toxicity in seven patients and one patient had grade 3 nausea and vomiting. One patient died because of neutropenic fever. Seven out of the 12 patients who could be evaluated regarding QOL presented an improvement in their overall health status and functional QOL scores over the course of the treatment. CONCLUSIONS: CFL is an active outpatient protocol with tolerable toxicity and a favorable QOL impact. Larger studies are warranted, in order to confirm these results.
Downloads
References
Gebbia V, Testa A, Valenza R, et al. A phase II study of levo- folinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma. Oncology. 1993;50(6):490-4.
Lee JJ, Jeng JH, Wang HM, et al. Univariate and multivariate analysis of prognostic significance of betel quid chewing in squamous cell carcinoma of buccal mucosa in Taiwan. J Surg Oncol. 2005;91(1):41-7.
Pignon JP, Bourhis J, Domenge C, Designé L. Chemo- therapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta- Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-55.
Clavel M, Vermorken JB, Cognetti F, et al. Randomized com- parison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin
(C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521-6.
Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24(17):2644-52.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Or- ganization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer. 1990;65(8):1864-6.
Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res. 1993;2(2):129-40.
Souza RCC, Barros CAA, Souza RRL, et al. Avaliação da qualidade de vida de doentes de carcinoma retal, submetidos à ressecção com preservação esfincteriana ou à amputação abdômino-perineal. Evaluation of life quality of sick people of rectal carcinoma, submitted to the resection with sphincter preservation or the abdominoperineal amputation]. Rev Bras Colo-proctol. 2005;25(3):235-40.
Samano ES, Goldenstein PT, Ribeiro Lde M, et al. Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J. 2004;122(2):60-3.
National Cancer Institute. CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http:// ctep.cancer.gov/reporting/ctc.html. Accessed in 2007 (Nov 27).
Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(1):78-92.
Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group ran- domized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69-76.
Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcino- mas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005;23(13):3008-15.
Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004;96(22):1714-17.
Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890-900.
Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol. 2006;24(17):2653-8.
Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-7.
Vokes EE, Schilsky RL, Weichselbaum RR, et al. Cisplatin, 5- fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989;63(6 Suppl):1048-53.
